We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,259 hedge funds and large institutions have $80B invested in Bristol-Myers Squibb in 2024 Q3 according to their latest regulatory filings, with 266 funds opening new positions, 820 increasing their positions, 929 reducing their positions, and 130 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more first-time investments, than exits

New positions opened: 266 | Existing positions closed: 130

50% more funds holding in top 10

Funds holding in top 10: 1827 (+9)

25% more capital invested

Capital invested by funds: $63.8B → $80B (+$16.2B)

5% more funds holding

Funds holding: 2,1482,259 (+111)

0.63% more ownership

Funds ownership: 75.77%76.4% (+0.63%)

5% less call options, than puts

Call options by funds: $1.88B | Put options by funds: $1.99B

12% less repeat investments, than reductions

Existing positions increased: 820 | Existing positions reduced: 929

Holders
2,259
Holders Change
+111
Holders Change %
+5.17%
% of All Funds
32.43%
Holding in Top 10
27
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+50%
% of All Funds
0.39%
New
266
Increased
820
Reduced
929
Closed
130
Calls
$1.88B
Puts
$1.99B
Net Calls
-$109M
Net Calls Change
+$35.1M
Name Holding Trade Value Shares
Change
Change in
Stake
AAMU
301
AEGON Asset Management (UK)
United Kingdom
$13.2M -$2.63M -56,106 -18%
PAG
302
Private Advisor Group
New Jersey
$13.2M -$497K -10,589 -4%
MME
303
Meag Munich Ergo
Germany
$13.1M +$9.15M +194,981 +339%
VPC
304
Vestal Point Capital
New York
$12.9M -$11.7M -250,000 -50%
Impax Asset Management Group
305
Impax Asset Management Group
United Kingdom
$12.9M -$121K -2,574 -1%
SMFG
306
Sumitomo Mitsui Financial Group
Japan
$12.8M +$1.51M +32,107 +15%
SC
307
Saturna Capital
Washington
$12.6M -$12.1M -258,383 -52%
GH
308
GAM Holding
Switzerland
$12.5M +$81.3K +1,733 +0.7%
CLOS
309
Compagnie Lombard Odier SCmA
Switzerland
$12.4M
YCM
310
Yousif Capital Management
Michigan
$12.3M -$129K -2,740 -1%
CM
311
Capital Management
Virginia
$12.3M +$1.46M +31,103 +15%
EDRH
312
Edmond de Rothschild Holding
Switzerland
$12.3M -$479K -10,215 -4%
CL
313
Choreo LLC
Illinois
$12.2M +$5.27M +112,428 +96%
OC
314
Oppenheimer & Co
New York
$12.1M +$1.45M +30,872 +15%
GHAM
315
Gilman Hill Asset Management
Connecticut
$12M -$58.4K -1,244 -0.5%
MAM
316
Martingale Asset Management
Massachusetts
$11.9M -$1.19M -25,424 -10%
Brown Advisory
317
Brown Advisory
Maryland
$11.8M -$165K -3,524 -2%
Grantham, Mayo, Van Otterloo & Co (GMO)
318
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$11.8M -$12.8M -272,273 -54%
Fisher Asset Management
319
Fisher Asset Management
Washington
$11.7M -$71.2K -1,518 -0.7%
CB
320
Community Bank
New York
$11.7M +$350K +7,463 +3%
SWP
321
Stratos Wealth Partners
Ohio
$11.5M +$883K +18,819 +9%
ACM
322
Aquatic Capital Management
Illinois
$11.4M -$27.6M -588,400 -73%
RRAM
323
River Road Asset Management
Kentucky
$11.2M -$195K -4,151 -2%
Allspring Global Investments
324
Allspring Global Investments
North Carolina
$11.1M -$15.2M -323,605 -60%
BPA
325
Beacon Pointe Advisors
California
$11.1M -$642K -13,675 -6%

BMY Hedge Fund Activity: Q3 2024 in Review

2,259 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2024, worth a combined $80B — up 25% from $63.8B a quarter earlier.

Buyers outnumbered sellers: 266 funds opened new BMY positions and 130 closed out — a net gain of 136 holders — while 820 added to existing stakes and 929 trimmed.

The largest buyer was Bank of New York Mellon, adding an estimated $331M. The largest seller was Capital International Investors, cutting an estimated $599M.

  • 2,259 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2024, up from 2,148 in Q2 2024.
  • Funds reported $80B of Bristol-Myers Squibb stock for Q3 2024, up 25% quarter-over-quarter.
  • 266 funds opened new Bristol-Myers Squibb positions in Q3 2024 and 130 closed out, a net change of +136 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2024 was Bank of New York Mellon, an estimated $331M added.
  • The largest Bristol-Myers Squibb seller in Q3 2024 was Capital International Investors, an estimated $599M sold.

Based on aggregated 13F filings for Q3 2024.